Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totalling 20,400 shares, a decline of 20.0% from the May 31st total of 25,500 shares. Based on an average daily trading volume, of 31,300 shares, the days-to-cover ratio is presently 0.7 days. Currently, 4.9% of the company’s stock are sold short.
Dermata Therapeutics Trading Down 4.2 %
Shares of DRMA stock opened at $2.29 on Tuesday. The stock’s fifty day simple moving average is $3.83 and its 200-day simple moving average is $5.88. Dermata Therapeutics has a 1-year low of $2.10 and a 1-year high of $26.55. The company has a market capitalization of $1.01 million, a price-to-earnings ratio of -0.08 and a beta of 0.75.
Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) last issued its earnings results on Wednesday, May 15th. The company reported ($7.05) EPS for the quarter.
Institutional Inflows and Outflows
About Dermata Therapeutics
Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
See Also
- Five stocks we like better than Dermata Therapeutics
- How to buy stock: A step-by-step guide for beginners
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- How to Invest in Blue Chip Stocks
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.